AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26388067 — intervention group
Group type: COMPARATOR
Intervention: Surgical removal of impacted lower third molars in normal-weight patients
Number of subjects: 560
Study 23948632 — intervention group
Group type: EXPERIMENTAL
Intervention: s-allele of the 5-HTTLPR
Number of subjects: 112
Study 23948632 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR
Number of subjects: 112
Study 23948632 — intervention group
Group type: EXPERIMENTAL
Intervention: MDP patients
Number of subjects: 112
Study 21631494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual feverfew/ginger
Number of subjects: 60
Study 21631494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17595032 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Preparation Rich in Growth Factors (PRGF)
Number of subjects: 0
Study 17595032 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 0
Study 16468084 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH-CPSI total score
Number of subjects: 174
Study 16468084 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH-CPSI pain score
Number of subjects: 174
Study 16468084 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH-CPSI quality of life score
Number of subjects: 174
Study 16468084 — intervention group
Group type: EXPERIMENTAL
Intervention: NIH-CPSI urinary score
Number of subjects: 174
Study 12956892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 5 days
Number of subjects: 17
Study 12956892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 10 days
Number of subjects: 17
Study 12956892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (40 mg/kg/day in 3 divided doses) for 15 days
Number of subjects: 17
Study 10855738 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril/verapamil (2 mg/180 mg)
Number of subjects: 226
Study 10855738 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril (2 mg)
Number of subjects: 226
Study 10855738 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (240 mg)
Number of subjects: 226
Study 9115527 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen plus a 15‐minute tepid sponge bath
Number of subjects: 20
Study 9115527 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen alone
Number of subjects: 20
Study 1288925 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (warming needle and point injection)
Number of subjects: 41
Study 1288925 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 41
Study 2871418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU capsules distributed twice, 1-3 months and 6 months after baseline)
Number of subjects: 229
Study 2871418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 229
Study 2871418 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 229
Study 31086274 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired corticospinal–motoneuronal stimulation (PCMS)
Number of subjects: 11
Study 31086274 — intervention group
Group type: COMPARATOR
Intervention: Control (100 peripheral nerve stimuli)
Number of subjects: 11
Study 29198731 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (NSAID)
Number of subjects: 544
Study 29198731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study 27750250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (6.0-8.0 MJ) - high carbohydrate
Number of subjects: 87
Study 27750250 — intervention group
Group type: COMPARATOR
Intervention: Low-energy diet (6.0-8.0 MJ) - moderate carbohydrate with increased protein
Number of subjects: 87
Study 27750250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diet groups
Number of subjects: 87
Study 24373754 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sevoflurane for 3 min via face mask with tidal volume of 2.2 ml kg(‐1) (Group 1)
Number of subjects: 48
Study 24373754 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sevoflurane for 3 min via face mask with tidal volume of 8 ml kg(‐1) (Group 2)
Number of subjects: 48
Study 24373754 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sevoflurane for 3 min via face mask with tidal volume of 12 ml kg(‐1) (Group 3)
Number of subjects: 48
Study 22839514 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 21.0±5 mg/day
Number of subjects: 200
Study 22839514 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate 87.7±7.6 mg/day
Number of subjects: 200
Study 20370859 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention clinic
Number of subjects: 43
Study 20370859 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 17514383 — intervention group
Group type: EXPERIMENTAL
Intervention: EBVS LigaSure V (group A)
Number of subjects: 24
Study 17514383 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic shears harmonic scalpel (HS) (group B)
Number of subjects: 24
Study 15983321 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/day)
Number of subjects: 14
Study 12207676 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol-narrow-band UVB
Number of subjects: 28
Study 12207676 — intervention group
Group type: COMPARATOR
Intervention: Narrow-band UVB
Number of subjects: 28
Study 10476942 — intervention group
Group type: EXPERIMENTAL
Intervention: nHuIFN-alpha 150 IU TID
Number of subjects: 0
Study 10476942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8911977 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 577
Study 8911977 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 577
Study 1866749 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 220
Study 1866749 — intervention group
Group type: COMPARATOR
Intervention: General medical wards
Number of subjects: 220
Study 7169630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus fading
Number of subjects: 24
Study 7169630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus delay
Number of subjects: 24
Study 7169630 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement only
Number of subjects: 24
Study 30704933 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 93
Study 30704933 — intervention group
Group type: COMPARATOR
Intervention: CICC
Number of subjects: 93
Study 30587273 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) using inverse variance weighted (IVW) method and MR-Egger
Number of subjects: 0
Study 26948160 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational audiovisual condition
Number of subjects: 22
Study 26948160 — intervention group
Group type: COMPARATOR
Intervention: Neutral audiovisual condition
Number of subjects: 22
Study 26948160 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study 23861004 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants instructed to avoid thinking about nonemotional targets
Number of subjects: 0
Study 23861004 — intervention group
Group type: COMPARATOR
Intervention: Participants instructed to think about nonemotional targets
Number of subjects: 0
Study 22309471 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused cognitive behavioral therapy (FCBT)
Number of subjects: 49
Study 19171500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125mg/d
Number of subjects: 107
Study 19171500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25mg/d
Number of subjects: 107
Study 19171500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.50mg/d
Number of subjects: 107
Study 19171500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75mg/d
Number of subjects: 107
Study 19171500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 18254226 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate therapy for 12 months
Number of subjects: 49
Study 18254226 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate therapy
Number of subjects: 49
Study 16390021 — intervention group
Group type: COMPARATOR
Intervention: 185 MBq of 131I
Number of subjects: 59
Study 16390021 — intervention group
Group type: EXPERIMENTAL
Intervention: 370 MBq of 131I
Number of subjects: 59
Study 9706947 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty without pneumatic tourniquet
Number of subjects: 24
Study 9706947 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty with pneumatic tourniquet
Number of subjects: 24
Study 8588791 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose hyoscine
Number of subjects: 47
Study 8588791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 47
Study 8588791 — intervention group
Group type: COMPARATOR
Intervention: Placebo hyoscine and placebo pyridostigmine
Number of subjects: 47
Study 8588791 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose hyoscine and pyridostigmine
Number of subjects: 47
Study 2089088 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 31
Study 2089088 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 31
Study 112475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (160 mg per day)
Number of subjects: 44
Study 112475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30829892 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity training model for dynamic ONSD measurement using ETT cuff volumes of 0.1 mL, 0.2 mL, and 0.3 mL.
Number of subjects: 30
Study 29927860 — intervention group
Group type: EXPERIMENTAL
Intervention: Annular Closure Device (ACD)
Number of subjects: 0
Study 29927860 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lumbar Discectomy (Control)
Number of subjects: 0
Study 28928601 — intervention group
Group type: EXPERIMENTAL
Intervention: RVA pacing (n = 30)
Number of subjects: 60
Study 28928601 — intervention group
Group type: COMPARATOR
Intervention: RVOT pacing (n = 30)
Number of subjects: 60
Study 25428708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued memories (prioritized memory item)
Number of subjects: 0
Study 25428708 — intervention group
Group type: COMPARATOR
Intervention: Uncued memories (non-prioritized memory item)
Number of subjects: 0
Study 25428708 — intervention group
Group type: COMPARATOR
Intervention: No memory items prioritized by a retro-cue
Number of subjects: 0
Study 25005893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1× hydration
Number of subjects: 26
Study 25005893 — intervention group
Group type: EXPERIMENTAL
Intervention: 2× hydration
Number of subjects: 26
Study 25005893 — intervention group
Group type: COMPARATOR
Intervention: no hydration
Number of subjects: 26
Study 22024475 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Infant Transaction program (MITP)
Number of subjects: 106
Study 22024475 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study 19387899 — intervention group
Group type: EXPERIMENTAL
Intervention: Information Communication Technology (ICT) guidance
Number of subjects: 52
Study 19387899 — intervention group
Group type: COMPARATOR
Intervention: Conventional face-to-face guidance
Number of subjects: 52
Study 17151807 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 GalU of alpha-galactosidase
Number of subjects: 8
Study 17151807 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 GalU of alpha-galactosidase
Number of subjects: 8
Study 17151807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14674932 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg oral, bedtime)
Number of subjects: 16
Study 14674932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11892891 — intervention group
Group type: EXPERIMENTAL
Intervention: Declarative knowledge under explicit learning conditions
Number of subjects: 0
Study 11892891 — intervention group
Group type: EXPERIMENTAL
Intervention: Declarative knowledge under implicit learning conditions
Number of subjects: 0
Study 11892891 — intervention group
Group type: EXPERIMENTAL
Intervention: Declarative knowledge
Number of subjects: 0
Study 9020283 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide and carboplatin with GM-CSF (molgramostim)
Number of subjects: 44
Study 9020283 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (5 microg/kg/d)
Number of subjects: 44
Study 9020283 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6 with GM-CSF
Number of subjects: 44
Study 8490637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 71
Study 8490637 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 71
Study 8490637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behavioral treatment and desipramine
Number of subjects: 71
Study 8490637 — intervention group
Group type: COMPARATOR
Intervention: High cluster B score
Number of subjects: 71
Study 3829579 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 140 mg
Number of subjects: 9
Study 3829579 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 280 mg
Number of subjects: 9
Study 3829579 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (therapeutic dose range)
Number of subjects: 9
Study 3829579 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 7.5 mg
Number of subjects: 9
Study 3829579 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 15 mg
Number of subjects: 9
Study 3829579 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 30 mg
Number of subjects: 9
Study 3829579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30799638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 302
Study 29718354 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBirth Program (coaching targeting implementation of Checklist with data feedback and action planning)
Number of subjects: 120
Study 29718354 — intervention group
Group type: EXPERIMENTAL
Intervention: BetterBirth Program
Number of subjects: 120
Study 29718354 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 120
Study 27502703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of 59.4-60 Gy
Number of subjects: 33566
Study 27502703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of 61-69 Gy
Number of subjects: 33566
Study 27502703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of ≥70 Gy
Number of subjects: 33566
Study 27502703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of 66 Gy
Number of subjects: 33566
Study 27502703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of 70 Gy
Number of subjects: 33566
Study 27502703 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose of ≥71 Gy
Number of subjects: 33566
Study 27502703 — intervention group
Group type: COMPARATOR
Intervention: Comparison of 66 Gy vs ≥71 Gy
Number of subjects: 33566
Study 26556393 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic Pulsed Current (MPC)
Number of subjects: 20
Study 26556393 — intervention group
Group type: COMPARATOR
Intervention: Burst-Modulated Alternating Current (BMAC)
Number of subjects: 20
Study 22999331 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold(®)IMT training, 5 times per week for 6 weeks
Number of subjects: 54
Study 22999331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 20510974 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 29
Study 20510974 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 29
Study 20510974 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 18388724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberglass casts
Number of subjects: 34
Study 18388724 — intervention group
Group type: COMPARATOR
Intervention: Plaster casts
Number of subjects: 34
Study 12436219 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual timing of blood counts
Number of subjects: 8
Study 12436219 — intervention group
Group type: COMPARATOR
Intervention: Standard twice a week G-CSF prophylaxis
Number of subjects: 8
Study 9579238 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms oral desmopressin without a meal (Day B)
Number of subjects: 16
Study 9579238 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms oral desmopressin with a standard meal (Day C)
Number of subjects: 16
Study 9579238 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms oral desmopressin 1.5 hours after a standard meal (Day D)
Number of subjects: 16
Study 9579238 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no meal (Day A)
Number of subjects: 16
Study 9579238 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatment days (B, C, D)
Number of subjects: 16
Study 7699968 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg per day for three days
Number of subjects: 30
Study 7699968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2566284 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium without glycopyrronium
Number of subjects: 80
Study 2566284 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 80
Study 2566284 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 80
Study 923185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 16
Study 31399245 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Number of subjects: 362
Study 27988297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glutathione (GSH) treatment for 6 months
Number of subjects: 0
Study 27988297 — intervention group
Group type: COMPARATOR
Intervention: Increasing GGT activity in sputum
Number of subjects: 0
Study 25858281 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking and nutrition (W/N) group
Number of subjects: 227
Study 25858281 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (W) group
Number of subjects: 227
Study 25858281 — intervention group
Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 227
Study 23711530 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT-guided antibiotic therapy; n = 20
Number of subjects: 81
Study 23711530 — intervention group
Group type: COMPARATOR
Intervention: No PCT guidance; n = 31
Number of subjects: 81
Study 21841092 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM) of warfarin therapy
Number of subjects: 11
Study 21841092 — intervention group
Group type: COMPARATOR
Intervention: Physician management of warfarin therapy
Number of subjects: 11
Study 21841092 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM)
Number of subjects: 11
Study 21841092 — intervention group
Group type: COMPARATOR
Intervention: Patient self-management (PSM) and Physician management
Number of subjects: 11
Study 18555238 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose GnRH agonist (GnRH‐a) flare-up protocol
Number of subjects: 42
Study 18555238 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 42
Study 17165022 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 14
Study 17165022 — intervention group
Group type: COMPARATOR
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 14
Study 15534050 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi uptake in benign lesions
Number of subjects: 75
Study 15534050 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-sestamibi uptake in carcinomas
Number of subjects: 75
Study 15534050 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion size < 1 cm
Number of subjects: 75
Study 15534050 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with proliferative cellular activity, multidrug resistance expression, or receptor status
Number of subjects: 75
Study 11172833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 1 mg
Number of subjects: 48
Study 11172833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 3 mg
Number of subjects: 48
Study 11172833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate 5 mg
Number of subjects: 48
Study 11172833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11172833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix acetate (1, 3, or 5 mg)
Number of subjects: 48
Study 9527417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water, n = 16)
Number of subjects: 32
Study 9527417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic product (mixture of chlorexidine, benzalkonium chloride and benzylic alcohol, n = 16)
Number of subjects: 32
Study 7523562 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IGF-I (rhIGF-I) 40 micrograms/kg
Number of subjects: 9
Study 7523562 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 2895786 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 12
Study 2895786 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 12
Study 2895786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30486682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day carvacrol
Number of subjects: 2
Study 30486682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day carvacrol
Number of subjects: 2
Study 30979653 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Number of subjects: 58
Study 30979653 — intervention group
Group type: COMPARATOR
Intervention: Monopolar electrocautery
Number of subjects: 58
Study 28000167 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban
Number of subjects: 0
Study 28000167 — intervention group
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 0